Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of QCC374

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: QCC374
Drug: Placebo

First Posted Date: 2014-09-22

Last Posted Date: 2016-03-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 66

Registration Number: NCT02245828

Locations: 🇬🇧
Novartis Investigative Site, Mid Glamorgan, Wales, United Kingdom

Study of Afuresertib Combined With Paclitaxel in Gastric Cancer

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Afuresertib
Drug: Paclitaxel

First Posted Date: 2014-09-15

Last Posted Date: 2017-04-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 29

Registration Number: NCT02240212

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: QVA149
Drug: QVA149 Placebo

First Posted Date: 2014-09-08

Last Posted Date: 2018-08-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 38

Registration Number: NCT02233543

Locations: 🇸🇪
Novartis Investigative Site, Uppsala, Sweden

Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks

Phase 4

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Fingolimod

First Posted Date: 2014-09-04

Last Posted Date: 2021-02-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 6

Registration Number: NCT02232061

Locations: 🇮🇹
Novartis Investigative Site, Napoli, Italy

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

Phase 2

Completed

Conditions: Relapsed B-cell Acute Lymphoblastic Leukemia
Refractory B-cell Acute Lymphoblastic Leukemia
B-cell Acute Lymphoblastic Leukemia

Interventions: Biological: CTL019 T-cells

First Posted Date: 2014-08-28

Last Posted Date: 2020-11-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 75

Registration Number: NCT02228096

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸
Childrens Hospital Los Angeles SC, Los Angeles, California, United States

and more 10 locations

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

Phase 3

Completed

Conditions: Chronic Heart Failure With Reduced Ejection Fraction

Interventions: Drug: LCZ696

First Posted Date: 2014-08-27

Last Posted Date: 2019-02-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1980

Registration Number: NCT02226120

Locations: 🇬🇧
Novartis Investigative Site, Worcester, United Kingdom

Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: cKIT-positive Solid Tumors
AML

Interventions: Drug: LOP628

First Posted Date: 2014-08-20

Last Posted Date: 2016-04-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3

Registration Number: NCT02221505

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation

Phase 1

Completed

Conditions: Kidney Transplantation

Interventions: Biological: CFZ533
Drug: Tacrolimus (Tac)
Drug: Mycophenolate mofetil (MMF)
Drug: Corticosteroids (CS)
Biological: anti-IL2 Induction

First Posted Date: 2014-08-15

Last Posted Date: 2021-09-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 59

Registration Number: NCT02217410

Locations: 🇳🇱
Novartis Investigative Site, Rotterdam, Netherlands

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Neoplasms, Breast

Interventions: Drug: Lapatinib
Biological: Trastuzumab
Drug: Aromatase Inhibitors (AIs)

First Posted Date: 2014-08-11

Last Posted Date: 2021-10-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT02213042

Locations: 🇹🇭
Novartis Investigative Site, Phitsanulok, Thailand

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Phase 1

Terminated

Conditions: Metastatic Colorectal Cancer
Squamous Cell Carcinoma of Head and Neck (SCCHN)

Interventions: Drug: INC280
Drug: cetuximab

First Posted Date: 2014-07-31

Last Posted Date: 2019-01-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 13

Registration Number: NCT02205398

Locations: 🇪🇸
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
🇺🇸
Massachusetts General Hospital Head & Neck, Boston, Massachusetts, United States
🇺🇸
University of Utah / Huntsman Cancer Institute Onc Dept, Salt Lake City, Utah, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy